ID   KMOE-2
AC   CVCL_1332
SY   KMOE2; Kmoe2
DR   CLO; CLO_0007114
DR   CLDB; cl3034
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03473322
DR   CCLE; KMOE2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   Cell_Model_Passport; SIDM01019
DR   ChEMBL-Cells; CHEMBL3308236
DR   ChEMBL-Targets; CHEMBL2366347
DR   Cosmic; 787445
DR   Cosmic; 907280
DR   Cosmic; 975262
DR   Cosmic; 1012079
DR   Cosmic; 1465969
DR   Cosmic; 2131542
DR   Cosmic; 2306213
DR   Cosmic-CLP; 907280
DR   DepMap; ACH-002258
DR   DSMZ; ACC-37
DR   GDSC; 907280
DR   GEO; GSM1446748
DR   GEO; GSM1669991
DR   IARC_TP53; 21434
DR   LINCS_LDP; LCL-1058
DR   PharmacoDB; KMOE2_757_2019
DR   Wikidata; Q54900132
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=6949905;
RX   PubMed=16408098;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 24.2 hours (PubMed=6949905); ~40-50 hours (DSMZ).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Heterozygous for NRAS p.Gln61Arg (c.182A>G) (ClinVar=VCV000013900) (CCLE; Cosmic-CLP).
CC   Sequence variation: Homozygous for TP53 p.Val272Met (c.814G>A) (ClinVar=VCV000185814) (CCLE; Cosmic-CLP).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.41%; Native American=0.02%; East Asian, North=78.12%; East Asian, South=19.8%; South Asian=1.43%; European, North=0.23%; European, South=0% (PubMed=30894373).
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 8,11
ST   D16S539: 9,11
ST   D5S818: 8,10
ST   D7S820: 10
ST   TH01: 6,9
ST   TPOX: 9
ST   vWA: 14,17
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_W022 ! KMOE-1
SX   Female
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=6949905; DOI=10.1007/BF00410534;
RA   Okano H., Okamura J., Yagawa K., Tasaka H., Motomura S.;
RT   "Human erythroid cell lines derived from a patient with acute
RT   erythremia.";
RL   J. Cancer Res. Clin. Oncol. 102:49-55(1981).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//